Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression


Lead Sponsor: University of Leeds

Collaborator: The Leeds Teaching Hospitals NHS Trust

Source University of Leeds
Brief Summary

Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

Overall Status Completed
Start Date 2003-09-01
Completion Date 2004-04-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups. 6 months
Enrollment 42

Intervention Type: Drug

Intervention Name: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD

Arm Group Label: 1

Intervention Type: Drug

Intervention Name: Valsartan 160mg OD; Moxonidine 400mcg OD

Arm Group Label: 2



Inclusion Criteria: - Recently diagnosed essential hypertension (within 6 months). - Age 25 to 80 years; Weight < 100kg. - Sinus rhythm without significant ventricular or atrial ectopy. Exclusion Criteria: - Current angiotensin II receptor antagonist or ACE Inhibitor treatment. - Contra-indication to any of the protocol anti-hypertensive agents. - Angina requiring treatment with a Beta blocker or calcium antagonist - Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy. - Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).



Minimum Age:

25 Years

Maximum Age:

80 Years

Healthy Volunteers:


Overall Official
Last Name Role Affiliation
John P Greenwood, MBChB, PhD Principal Investigator Leeds University
Facility: Leeds Teaching Hospital NHS Trust
Location Countries

United Kingdom

Verification Date


Responsible Party

Type: Principal Investigator

Investigator Affiliation: University of Leeds

Investigator Full Name: Dr JP Greenwood

Investigator Title: Senior Lecturer

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: 1

Type: Experimental

Description: Neurohormonal stimulatory arm

Label: 2

Type: Experimental

Description: Neurohormonal inhibitory arm

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on, this will be updated automatically on our website as well.

Clinical Research News